INNV / InnovAge Holding Corp. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

INNV / Innovus Pharmaceuticals, Inc. 15-12G - - FORM 15-12G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-52991 Innovus Pharmaceuticals, Inc. (Exact name of registrant as specif

As filed with the Securities and Exchange Commission on February 25, 2020

As filed with the Securities and Exchange Commission on February 25, 2020 Registration No.

INNV / Innovus Pharmaceuticals, Inc. S-8 POS - - FORM S-8 POS

As filed with the Securities and Exchange Commission on February 25, 2020 Registration No.

As filed with the Securities and Exchange Commission on February 25, 2020

As filed with the Securities and Exchange Commission on February 25, 2020 Registration No.

As filed with the Securities and Exchange Commission on February 25, 2020

As filed with the Securities and Exchange Commission on February 25, 2020 Registration No.

As filed with the Securities and Exchange Commission on February 25, 2020

As filed with the Securities and Exchange Commission on February 25, 2020 Registration No.

As filed with the Securities and Exchange Commission on February 25, 2020

As filed with the Securities and Exchange Commission on February 25, 2020 Registration No.

As filed with the Securities and Exchange Commission on February 25, 2020

As filed with the Securities and Exchange Commission on February 25, 2020 Registration No.

INNV / Innovus Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2020 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Comm

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2020 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Comm

INNV / Innovus Pharmaceuticals, Inc. / LGH Investments, LLC Passive Investment

Item 1. (a) Name of Issuer Innovus Pharmaceuticals, INC. (b) Address of Issuer's Principal Executive Offices 8845 Rehco Road San Diego, California 92121 Item 2. (a) Name of Person Filing LGH Investments, LLC (b) Address of Principal Business Office or, if none, Residence LGH Investments, LLC 30 North Gould Street, Suite R Sheridan, Wyoming 82801 (c) Citizenship Wyoming (d) Title of Class of Securi

Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended September 30, 2019 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991

AYTU / Aytu BioScience, Inc. 425 - Merger Prospectus - 425

AYTU / Aytu BioScience, Inc. 425 - Merger Prospectus - 425

425 1 aytu425.htm 425

INNV / Innovus Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Com

Agreement and Plan of Merger, dated as of September 12, 2019, by and among Aytu BioScience, Inc., Aytu Acquisition Sub, Inc. and Innovus Pharmaceuticals, Inc.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among AYTU BIOSCIENCE INC., AYTU ACQUISITION SUB, INC. and INNOVUS PHARMACEUTICALS, INC. Dated as of September 12, 2019 TABLE OF CONTENTS ARTICLE I THE MERGER 7 Section 1.01 The Merger. 7 Section 1.02 Closing. 7 Section 1.03 Effective Time. 7 Section 1.04 Effects of the Merger. 7 Section 1.05 Certificate of Incorporation; By-Laws. 8 Section 1.06 Dire

Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals Acquisition Gives Aytu Timely Entry into Growing Consumer Healthcare Market with a Portfolio of Over 30 Products that Generated $24M of Revenue During Past Four Quarter

Exhibit 99.1 Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals Acquisition Gives Aytu Timely Entry into Growing Consumer Healthcare Market with a Portfolio of Over 30 Products that Generated $24M of Revenue During Past Four Quarters Combination Will Create Specialty Rx and Consumer Pharma Company with Revenue of $31M New Products, Robust Cross-Selling, and Operation

INNV / Innovus Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Com

Agreement and Plan of Merger, dated as of September 12, 2019, by and among Aytu BioScience, Inc., Aytu Acquisition Sub, Inc. and Innovus Pharmaceuticals, Inc.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among AYTU BIOSCIENCE INC., AYTU ACQUISITION SUB, INC. and INNOVUS PHARMACEUTICALS, INC. Dated as of September 12, 2019 TABLE OF CONTENTS ARTICLE I THE MERGER 7 Section 1.01 The Merger. 7 Section 1.02 Closing. 7 Section 1.03 Effective Time. 7 Section 1.04 Effects of the Merger. 7 Section 1.05 Certificate of Incorporation; By-Laws. 8 Section 1.06 Dire

Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals Acquisition Gives Aytu Timely Entry into Growing Consumer Healthcare Market with a Portfolio of Over 30 Products that Generated $24M of Revenue During Past Four Quarter

Exhibit 99.1 Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals Acquisition Gives Aytu Timely Entry into Growing Consumer Healthcare Market with a Portfolio of Over 30 Products that Generated $24M of Revenue During Past Four Quarters Combination Will Create Specialty Rx and Consumer Pharma Company with Revenue of $31M New Products, Robust Cross-Selling, and Operation

INNV / Innovus Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 425

Filed by Innovus Pharmaceuticals, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and Deemed Filed Pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Innovus Pharmaceuticals, Inc. Commission File No.: 000-52991 Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals Acquisition Gives Aytu Timely Entry into Growing Consumer Health

Innovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior Quarter Sales & Marketing Expense as a Percentage of Total Revenue Declined to 41.7% for the three months ended June 30, 2019 Compared w

Exhibit 99.1 Innovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior Quarter Sales & Marketing Expense as a Percentage of Total Revenue Declined to 41.7% for the three months ended June 30, 2019 Compared with 75.6% in Comparable Period in the Prior Year Reduced Operating Loss by 21% Compared with both the Prior Quarter and Comparable Quarte

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commiss

INNV / Innovus Pharmaceuticals, Inc. 10-Q - Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended June 30, 2019 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991 INNO

Form of Promissory Note, dated August 8, 2019

Exhibit 4.1 PROMISSORY NOTE $1,000,000 August 8, 2019 (“Effective Date”) For value received, Innovus Pharmaceuticals, Inc., a Nevada corporation (“Borrower”), with its principal place of business at 8845 Rehco Road, San Diego, CA 92121, hereby promises to pay to [ ] (“Lender”), with its principal place of business at [ ], in lawful money of the United States of America, the principal amount of ONE

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissi

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissi

Innovus Pharmaceuticals Announces that its Delta Prime Savings Club E-Commerce Marketplace is on Track for Annual Sales of Approximately $3 million in 2019 Annual Sales Tracking to Exceed Previous Year Sales of $2 million

Exhibit 99.1 Innovus Pharmaceuticals Announces that its Delta Prime Savings Club E-Commerce Marketplace is on Track for Annual Sales of Approximately $3 million in 2019 Annual Sales Tracking to Exceed Previous Year Sales of $2 million SAN DIEGO, July 22, 2019 – Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutica

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissi

Innovus Pharmaceuticals Announces Progress in Fulfilling the Regulatory and Manufacturing Steps to Receive Market Authorization for FlutiCare® in Canada -Company Also Updates on Additional Revenue-Generating Activity in that Country

Innovus Pharmaceuticals Announces Progress in Fulfilling the Regulatory and Manufacturing Steps to Receive Market Authorization for FlutiCare® in Canada -Company Also Updates on Additional Revenue-Generating Activity in that Country SAN DIEGO, June 19, 2019 – Innovus Pharmaceuticals, Inc.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissio

INNV / Innovus Pharmaceuticals, Inc. S-8 - - FORM S-8

As filed with the Securities and Exchange Commission on June 7, 2019 Registration No.

INNOVUS PHARMACEUTICALS, INC. 2019 EQUITY INCENTIVE PLAN EFFECTIVE AS OF June 1, 2019

Exhibit 4.6 INNOVUS PHARMACEUTICALS, INC. 2019 EQUITY INCENTIVE PLAN EFFECTIVE AS OF June 1, 2019 SECTION 1. INTRODUCTION. The Company’s Board of Directors adopted this Innovus Pharmaceuticals, Inc. 2019 Equity Incentive Plan (the “Plan”) effective on the Effective Date. The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder value by offering Sel

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 innv201905298k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdict

Corporate Presentation

Exhibit 99.1

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissio

INNV / Innovus Pharmaceuticals, Inc. 10-Q Quarterly Report FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended March 31, 2019 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991 INN

Innovus Pharma Reports Quarterly Revenue for the First Quarter 2019 of $5.4 million, a 18.0% Increase From Comparable Quarter in the Prior Year Cash, inclusive of merchant processor holdback, of $2.9 million as of May 13, 2019

Exhibit 99.1 Innovus Pharma Reports Quarterly Revenue for the First Quarter 2019 of $5.4 million, a 18.0% Increase From Comparable Quarter in the Prior Year Cash, inclusive of merchant processor holdback, of $2.9 million as of May 13, 2019 SAN DIEGO, May 15, 2019 – Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company t

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commission

INNV / Innovus Pharmaceuticals, Inc. S-8 FORM S-8

S-8 1 innv20190424s8.htm FORM S-8 As filed with the Securities and Exchange Commission on April 30, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporatio

INNV / Innovus Pharmaceuticals, Inc. DEF 14A FORM DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissi

Innovus Pharma Announces FDA Approval of New ANDA for Supply of FlutiCare® Company Also Reaches Sales Milestone of 1,000 Units of FlutiCare® Sold per Day

Exhibit 99.1 Innovus Pharma Announces FDA Approval of New ANDA for Supply of FlutiCare® Company Also Reaches Sales Milestone of 1,000 Units of FlutiCare® Sold per Day San Diego, CA, April 18, 2019 – Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the

Corporate Presentation

Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 11, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissio

Innovus Pharma Reports Record Annual Revenue for Fiscal 2018 of $24.0 million in line with Previous Guidance and Product Gross Margins of 81% Revenue growth of 2.7x compared to Fiscal 2017 Revenues

Exhibit 99.1 Innovus Pharma Reports Record Annual Revenue for Fiscal 2018 of $24.0 million in line with Previous Guidance and Product Gross Margins of 81% Revenue growth of 2.7x compared to Fiscal 2017 Revenues SAN DIEGO, April 1, 2019 – Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovativ

Financial Statements and Exhibits

8-K 1 innv201903308k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdi

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Subsidiary Jurisdiction of Incorporation FasTrack Pharmaceuticals, Inc. Delaware Semprae Laboratories, Inc. Delaware Novalere, Inc. Delaware Supplement Hunt, Inc. Nevada Prime Savings Club, Inc. Nevada

Audited consolidated financial statements for Innovus Pharmaceutical Inc. as of and for the years-ended December 31, 2018 and 2017, respectively, as incorporated and filed within the Form 10-K on April 1, 2019.

10-K 1 innv2018123110k.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 Commission file number: 000-52991 INNOVUS PHARMACEUTICALS, INC. (Name of registrant as specified in its charter) Nevada 90-0814124 (St

CODE OF ETHICS

Exhibit 14.1 CODE OF ETHICS Innovus Pharmaceuticals, Inc. and subsidiaries (the "Company") is committed to conducting its business in compliance with all the applicable laws and regulations of the countries in which it operates and in accordance with high standards of business conduct. The Company strives to maintain the highest standard of accuracy, completeness and disclosure in its financial de

Certificate of Amendment to the Amended and Restated Articles of Incorporation, dated March 14, 2019.

Exhibit 3.1

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Nevada 000-52991 90-0814124 (State or Other Jurisdiction of Incorporation or Organi

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Nevada 000-52991 90-0814124 (State or Other Jurisdiction of Incorporation or Org

PROSPECTUS 139,317,017 Shares Common Stock

424B3 1 innv20190210424b3.htm FORM 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-229223 PROSPECTUS 139,317,017 Shares Common Stock This prospectus relates to the sale from time to time of up to 139,317,017 shares of common stock, par value $0.001 per share, of Innovus Pharmaceuticals, Inc. (“we,” “us,” or the “Company”) by the selling stockholders identified in this

INNV / Innovus Pharmaceuticals, Inc. FORM S-1/A

S-1/A 1 innv20190207s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on February 8, 2019 Registration No. 333-229223 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada (State or oth

INNV / Innovus Pharmaceuticals, Inc.

CORRESP 1 filename1.htm February 8, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Innovus Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333-229223) Ladies and Gentlemen: Innovus Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of the effectiveness of the Registration Statement on Form S-1 (File N

INNV / Innovus Pharmaceuticals, Inc. FORM DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

INNV / Innovus Pharmaceuticals, Inc. FORM S-1

Table of Contents As filed with the Securities and Exchange Commission on January 14, 2019 Registration No.

INNV / Innovus Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Financial Statements and Exhibits, Other Events

8-K 1 innv201901068k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2019 INNOVUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Nevada 000-52991 90-0814124 (State or Other Juri

Form of Securities Purchase Agreement, dated December 30, 2018 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 7, 2019).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 30, 2018, between Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and co

INNV / Innovus Pharmaceuticals, Inc. FORM PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Form of Securities Purchase Agreement and disclosure schedules thereto

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 30, 2018, between Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and co

Form of Series A, Series B and Series C Warrant filed as Exhibit 4.1 to the Registrant’s current report on Form 8-K, filed with the SEC on December 31, 2018 and incorporated herein by reference.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Letter Agreement by and between Innovus Pharmaceuticals, Inc. and H.C. Wainwright and Co., LLC, dated November 19, 2018 (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on December 31, 2018).

Exhibit 10.3 November 19, 2018 STRICTLY CONFIDENTIAL Innovus Pharmaceuticals, Inc. 8845 Rehco Road San Diego, CA 92122 Attn: Bassam Damaj, Ph.D., President and Chief Executive Officer Dear Dr. Damaj: This letter agreement (this “Agreement”) constitutes the agreement between Innovus Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as t

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Nevada 000-52991 90-0814124 (State or Other Jurisdiction of Incorporation or Org

INNOVUS PHARMACEUTICALS ANNOUNCES $3.17 MILLION Private placement

Exhibit 99.1 INNOVUS PHARMACEUTICALS ANNOUNCES $3.17 MILLION Private placement San Diego, CA, December 31, 2018 - Innovus Pharmaceuticals, Inc. (OTCQB: INNV) (“Innovus Pharma” or the “Company”), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory dis

Form of Registration Rights Agreement, dated December 30, 2018 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on December 31, 2018).

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 30, 2018, between Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities

Financial Statements and Exhibits

8-K 1 innv201811148k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jur

Innovus Pharma Reports Another New Quarterly Revenue Record of Approximately $7.4 million for the Third Quarter 2018 and $19.2 million for the First Nine Months of 2018 The Company is in its Fifth Consecutive Quarter of Net Revenue Growth and Working

Exhibit 99.1 Innovus Pharma Reports Another New Quarterly Revenue Record of Approximately $7.4 million for the Third Quarter 2018 and $19.2 million for the First Nine Months of 2018 The Company is in its Fifth Consecutive Quarter of Net Revenue Growth and Working Diligently Towards Exiting the Fourth Quarter 2018 Profitable SAN DIEGO, November 14, 2018 – Innovus Pharmaceuticals, Inc. (“Innovus Pha

INNV / Innovus Pharmaceuticals, Inc. FORM 10-Q (Quarterly Report)

10-Q 1 innv2018093010q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended September 30, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission Fil

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commiss

EX-99.1

Results of Operations and Financial Condition, Financial Statements and Exhibits

8-K 1 innv8kaug142018.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or othe

Innovus Pharma Reports New Quarterly Revenue Record of $7.3 million for the Second Quarter 2018 and Expands to Canadian Market Beyond Human™ Sales & Marketing Strategy Results in 258.7% Net Revenue Growth Compared to Same Period in 2017

Exhibit 99.1 Innovus Pharma Reports New Quarterly Revenue Record of $7.3 million for the Second Quarter 2018 and Expands to Canadian Market Beyond Human™ Sales & Marketing Strategy Results in 258.7% Net Revenue Growth Compared to Same Period in 2017 SAN DIEGO, August 14, 2018 – Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), today reported results for the second qu

INNV / Innovus Pharmaceuticals, Inc. QUARTERLY REPORT (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended June 30, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991 INNOVUS PHARMACEUTICAL

Innovus Pharma Signs Purchase Agreement with “Showcase – The Home of the Hottest Trends” to Sell the Company’s Apeaz® Cream for the Relief of Arthritis Pain in its 110 “Showcase” Retail Stores in the United States and Canada Apeaz® is the Fifth Compa

Exhibit 99.1 Innovus Pharma Signs Purchase Agreement with “Showcase – The Home of the Hottest Trends” to Sell the Company’s Apeaz® Cream for the Relief of Arthritis Pain in its 110 “Showcase” Retail Stores in the United States and Canada Apeaz® is the Fifth Company Product to Be Sold in Retails Stores in the U.S. and Canada San Diego, CA, August 10, 2018 – Innovus Pharmaceuticals, Inc. ("Innovus P

Financial Statements and Exhibits, Other Events

8-K 1 innv8kaug102018.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or othe

Innovus Pharmaceuticals Reports Preliminary Q2 2018 Sales Revenue of $6.6 million to $6.8 million Preliminary Quarterly Revenue Increase of 47-51% and Comparable 2017 Second Quarter Increase of 330-340% and Fiscal Year 2018 Net Revenue Annual Guidanc

Exhibit 99.1 Innovus Pharmaceuticals Reports Preliminary Q2 2018 Sales Revenue of $6.6 million to $6.8 million Preliminary Quarterly Revenue Increase of 47-51% and Comparable 2017 Second Quarter Increase of 330-340% and Fiscal Year 2018 Net Revenue Annual Guidance Adjusted Upwards to at Least $22 Million SAN DIEGO, July 17, 2018 – Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (OTCQB: INNV), to

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissio

EX-99.1

Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 innv8kmay292018.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 29, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other ju

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissio

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commission

Innovus Pharmaceuticals Reports Record Quarterly Revenue for the First Quarter 2018 of $4.5 million, Beating Previous Estimate and Net Loss Decrease of 28% Compared to the Same Quarterly Period in 2017 Quarterly Net Revenue Increase of 109% When Comp

EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 Innovus Pharmaceuticals Reports Record Quarterly Revenue for the First Quarter 2018 of $4.5 million, Beating Previous Estimate and Net Loss Decrease of 28% Compared to the Same Quarterly Period in 2017 Quarterly Net Revenue Increase of 109% When Compared to the First Quarter of 2017 SAN DIEGO, May 14, 2018 – Innovus Pharmaceuticals, Inc., (“Innovus P

INNV / Innovus Pharmaceuticals, Inc. QUARTERLY REPORT (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended March 31, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991 INNOVUS PHARMACEUTICA

INNV / Innovus Pharmaceuticals, Inc. DEFINITIVE PROXY STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissi

Employment Agreement, dated as of April 27, 2018, by and between Innovus Pharmaceuticals, Inc. and Ryan J. Selhorn (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 23, 2017)

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into by and between Ryan J. Selhorn (“you” or “your”) and Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”). This Agreement has an effective date of April 27, 2018 (the “Effective Date”). In consideration of the mutual covenants and promises made in this Agreement, you and the Company agree a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissio

Innovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 million to $4.4 million and Expects to Exit 2018 Profitable Year over Year Revenue Increase of 83% with Reduction in Net Loss o

Exhibit 99.1 Innovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 million to $4.4 million and Expects to Exit 2018 Profitable Year over Year Revenue Increase of 83% with Reduction in Net Loss of 53% in 2017 and Fiscal Year 2018 Net Revenue Annual Run Rate of At Least $18 million SAN DIEGO, April 2, 2018 – Innovus Pharmaceuticals

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissio

List of Subsidiaries (incorporated by reference to Exhibit 21.1 to the Company’s Annual Report on Form 10-K filed April 2, 2018)

Exhibit 21.1 Subsidiaries of the Registrant Subsidiary Jurisdiction of Incorporation FasTrack Pharmaceuticals, Inc. Delaware Semprae Laboratories, Inc. Delaware Novalere, Inc. Delaware

INNV / Innovus Pharmaceuticals, Inc. ANNUAL REPORT (Annual Report)

10-K 1 innv10kdec312017.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2017 Commission file number: 000-52991 INNOVUS PHARMACEUTICALS, INC. (Name of registrant as specified in its charter) Nevada 90-0814124 (State or other

Code of Ethics (incorporated by reference to Exhibit 14.1 to the Company’s Annual Report on Form 10-K filed April 2, 2018)

Exhibit 14.1 CODE OF ETHICS Innovus Pharmaceuticals, Inc. and subsidiaries (the "Company") is committed to conducting its business in compliance with all the applicable laws and regulations of the countries in which it operates and in accordance with high standards of business conduct. The Company strives to maintain the highest standard of accuracy, completeness and disclosure in its financial de

Financial Statements and Exhibits, Other Events

Untitled Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of inco

Innovus Pharma Signs Exclusive License and Distribution Agreement with Lavasta Pharma for ProstaGorx® in Certain Middle Eastern and North African Countries The Company to Receive an Upfront Payment plus Transfer Price on Minimum Annual Purchases Requ

Untitled Document Exhibit 99.1 Innovus Pharma Signs Exclusive License and Distribution Agreement with Lavasta Pharma for ProstaGorx? in Certain Middle Eastern and North African Countries The Company to Receive an Upfront Payment plus Transfer Price on Minimum Annual Purchases Requirements San Diego, Calif., January 23, 2018 ? Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the ?Company?) (OTCQB

Financial Statements and Exhibits, Other Events

Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2018 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation

Innovus Pharma Enters Into License and Distribution Agreement with Acerus Pharmaceuticals for the Commercialization of UriVarx® in Canada The Company to Receive an Upfront Payment and Minimum Order Quantities at a Pre-Agreed Transfer Price Plus up to

Ex99-1 Exhibit 99.1 Innovus Pharma Enters Into License and Distribution Agreement with Acerus Pharmaceuticals for the Commercialization of UriVarx? in Canada The Company to Receive an Upfront Payment and Minimum Order Quantities at a Pre-Agreed Transfer Price Plus up to CAD$1.65 Million in Sale Milestone Payments San Diego, CA, January 8, 2018 ? Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or t

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commi

Innovus Pharma Launches FlutiCare™ OTC Nasal Spray Allergy Relief in the U.S. Product Currently Expected to Generate $10-$15m in Additional Revenues Annually

Ex 99-1 Exhibit 99.1 Innovus Pharma Launches FlutiCare? OTC Nasal Spray Allergy Relief in the U.S. Product Currently Expected to Generate $10-$15m in Additional Revenues Annually San Diego, CA, November 14, 2017 ? Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the ?Company?) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and eff

Innovus Pharmaceuticals Reports Nine Month Net Revenue of $6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016 Quarterly and Year-to-Date Net Revenue Increase 18.0% and 105.8% When Compared to 2016 FlutiCare™ Launches on No

EX-99.1 2 ex99-1.htm PRESS RELEASE ISSUED NOVEMBER 14, 2017 Exhibit 99.1 Innovus Pharmaceuticals Reports Nine Month Net Revenue of $6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016 Quarterly and Year-to-Date Net Revenue Increase 18.0% and 105.8% When Compared to 2016 FlutiCare™ Launches on November 14, 2017 SAN DIEGO, November 14, 2017 – Innovus Pharmaceuticals, Inc.,

INNV / Innovus Pharmaceuticals, Inc. QUARTERLY REPORT (Quarterly Report)

10-Q 1 innv10qsep302017.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended September 30, 2017 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commis

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commi

Innovus Pharma Announces the Availability of the Full Label for its Nasal Drug FlutiCare™ for Allergy Symptom Relief on DailyMed FlutiCare™ is on Track for a November 2017 Launch in the U.S.

Blueprint Exhibit 99.1 Innovus Pharma Announces the Availability of the Full Label for its Nasal Drug FlutiCare? for Allergy Symptom Relief on DailyMed FlutiCare? is on Track for a November 2017 Launch in the U.S. San Diego, Calif., September 27, 2017 ? Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the ?Company?) (OTCQB Venture Market: INNV), an emerging over-the-counter (?OTC?) consumer good

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Comm

EX-99.1

EX-99.1 2 ex99-1.htm PRESENTATION Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 31, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissi

Innovus Pharmaceuticals Reports a Quarterly Net Revenue Increase of 99.2% and Net Loss Decrease of 74.1% Compared to the Same Period in 2016 FlutiCare™ on Track for Q4 2017 Launch

SEC Connect Exhibit 99.1 Innovus Pharmaceuticals Reports a Quarterly Net Revenue Increase of 99.2% and Net Loss Decrease of 74.1% Compared to the Same Period in 2016 FlutiCare™ on Track for Q4 2017 Launch SAN DIEGO, August 14, 2017 – Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company”) (OTCQB: INNV), today announced second quarter 2017 net revenue of $2.0 million compared to $1.0 mil

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commiss

INNV / Innovus Pharmaceuticals, Inc. QUARTERLY REPORT (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended June 30, 2017 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991 INNOVUS PHARMACEUTICAL

Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 19, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commission

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 19, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commission

EX-99.1

Untitled Document Exhibit 99.1

Innovus Pharma Signs Exclusive License and Distribution Agreement with Luminarie in Australia, New Zealand and the Philippines for Zestra® for Female Sexual Arousal Disorder and Zestra Glide® for Female Lubrication

SEC Connect Exhibit 99.1 Innovus Pharma Signs Exclusive License and Distribution Agreement with Luminarie in Australia, New Zealand and the Philippines for Zestra® for Female Sexual Arousal Disorder and Zestra Glide® for Female Lubrication San Diego, Calif., May 22, 2017 – Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events

8-K 1 innv8kmay102017.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdi

Innovus Pharma Signs Exclusive License and Distribution Agreement with Densmore for Zestra(R) for Female Sexual Arousal Disorder in France and Belgium

SEC Connect Exhibit 99.1 Innovus Pharma Signs Exclusive License and Distribution Agreement with Densmore for Zestra(R) for Female Sexual Arousal Disorder in France and Belgium San Diego, Calif., May 16, 2017 – Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended March 31, 2017 [ ] Transition Repo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended March 31, 2017 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991 INNOVUS PHARMACEUTICA

Innovus Pharmaceuticals Reports Quarterly Revenue for the First Quarter 2017 of $2.2 Million Company Achieved Year over Year Revenue Growth of 866% and Sequential Quarter over Quarter Growth of 29%

SEC Connect Exhibit 99.1 Innovus Pharmaceuticals Reports Quarterly Revenue for the First Quarter 2017 of $2.2 Million Company Achieved Year over Year Revenue Growth of 866% and Sequential Quarter over Quarter Growth of 29% SAN DIEGO, May 12, 2017 – Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (OTCQB: INNV), today announced first quarter 2017 net revenue of $2.2 million compared to $0.2 millio

Financial Statements and Exhibits, Results of Operations and Financial Condition

SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation)

Innovus Pharma Announces Commercial Partnership to Launch FlutiCare™ Under FDA Approved ANDA No. 207957 -FlutiCare™ Will be the Third Branded Fluticasone Propionate Nasal Spray Sold in the United States

SEC Connect Exhibit 99.1 Innovus Pharma Announces Commercial Partnership to Launch FlutiCare™ Under FDA Approved ANDA No. 207957 -FlutiCare™ Will be the Third Branded Fluticasone Propionate Nasal Spray Sold in the United States San Diego, Calif., May 9, 2017 – Innovus Pharmaceuticals, Inc. (the “Company” or "Innovus Pharma") (OTCQB Venture Market: INNV) and its partner West-Ward Pharmaceuticals In

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commission

Innovus Pharmaceuticals DEFINITIVE PROXY STATEMENT

SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

EMPLOYMENT AGREEMENT

SEC Connect Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into by and between Rauly Gutierrez (?you? or ?your?) and Innovus Pharmaceuticals, Inc., a Nevada corporation (the ?Company?). This Agreement has an effective date of September 23, 2016 (the ?Effective Date?). In consideration of the mutual covenants and promises made in this Agreement, you and the

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissi

Innovus Pharmaceuticals FORM S-8

S-8 1 innvs8apr122017.htm FORM S-8 As filed with the Securities and Exchange Commission on April 12, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporati

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissi

Innovus Pharmaceuticals Announces the Cash Redemption of All Outstanding Convertible Notes Reduces Current Debt Obligations by Approximately $1.3 Million

EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 Innovus Pharmaceuticals Announces the Cash Redemption of All Outstanding Convertible Notes Reduces Current Debt Obligations by Approximately $1.3 Million San Diego, Calif., March 22, 2017 – Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), today announced the cash redemption of all remaining outstanding convertible notes.

25,617,592 Shares of Common Stock

Filed pursuant to Rule 424(b)(4) Registration Statement No. 333-215851 PROSPECTUS 25,617,592 Shares of Common Stock This prospectus related to the offer and resale by the stockholder identified on page 62 of this prospectus (“Selling Stockholder”) of up to 25,617,592 shares of our common stock, issued in connection with the prior merger of Novalere FP, Inc., a Delaware corporation, with and into a

25,666,669 Shares of Common Stock Series A Warrants to Purchase 25,666,669 Shares of Common Stock Series B Warrants to Purchase 25,666,669 Shares of Common Stock

SEC Connect Filed pursuant to Rule 424(b)(1) Registration Statement No. 333-215851 PROSPECTUS 25,666,669 Shares of Common Stock Series A Warrants to Purchase 25,666,669 Shares of Common Stock Series B Warrants to Purchase 25,666,669 Shares of Common Stock Innovus Pharmaceuticals, Inc. (the ?Company?) is offering 25,666,669 shares of common stock, five-year warrants to purchase up to 25,666,669 sha

As filed with the Securities and Exchange Commission on March 14, 2017

S-1/A 1 innvs1-am2mar2017.htm AMENDMENT NO. 2 TO FORM S-1 As filed with the Securities and Exchange Commission on March 14, 2017 Registration No. 333-215851 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 2) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nev

Innovus Pharmaceuticals ESP

CORRESP 1 filename1.htm March 14, 2017 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Innovus Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333-215851) Ladies and Gentlemen: Innovus Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of the effectiveness of the Registration Statement on Form S-1 (File No.

Innovus Pharmaceuticals ESP

SEC Connect March 14, 2017 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: INNOVUS PHARMACEUTICALS, INC. Registration Statement on Form S-1 (Registration No. 333-215851) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (?Wainwright?), as placement agent for the referenced offering, hereby c

As filed with the Securities and Exchange Commission on March 13, 2017

As filed with the Securities and Exchange Commission on March 13, 2017 Registration No.

EX-10.42

EX-10.42 6 innvengagementletter.htm ENGAGEMENT AGREEMENT

Form of Placement Agent Warrant filed as Exhibit 4.3 to the Registrant's report on Amendment No. 1 to Form S-1 filed with the SEC on March 13, 2017 and incorporated herein by reference.

COMMON STOCK PURCHASE WARRANT INNOVUS PHARMACEUTICALS, INC. Warrant Shares: [ Initial Exercise Date: [, 2017 Issue Date: [, 2017 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (

Form of Securities Purchase Agreement filed as Exhibit 4.1 to the Registrant's report on Amendment No. 1 to Form S-1 filed with the SEC on March 13, 2017 and incorporated herein by reference.

SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of [ , 2017, between Innovus Pharmaceuticals, Inc.

Form of Series A and Series B Warrant filed as Exhibit 4.2 to the Registrant's report on Amendment No. 1 to Form S-1 filed with the SEC on March 13, 2017 and incorporated herein by reference.

SERIES [A/B] COMMON STOCK PURCHASE WARRANT INNOVUS PHARMACEUTICALS, INC. Warrant Shares: [ Initial Exercise Date: [, 2017 Issue Date: [, 2017 THIS SERIES [A/B] COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on

March [10],

March [10], 2017 STRICTLY CONFIDENTIAL Innovus Pharmaceuticals, Inc. 9171 Towne Centre Drive, Suite 440 San Diego, California 92122 Attention: Dr. Bassam Damaj, Chief Executive Officer Dear Mr. Damaj: Reference is made to the engagement agreement (the ?Engagement Agreement?), dated January 17, 2017, by and between Innovus Pharmaceuticals, Inc. (the ?Company?) and Rodman & Renshaw, a unit of H.C. W

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Subsidiary Jurisdiction of Incorporation FasTrack Pharmaceuticals, Inc. Delaware Semprae Laboratories, Inc. Delaware Novalere, Inc. Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2016 Commission file number: 000-52991 INNOV

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2016 Commission file number: 000-52991 INNOVUS PHARMACEUTICALS, INC. (Name of registrant as specified in its charter) Nevada 90-0814124 (State or other jurisdiction of incorporation or organizat

Innovus Pharmaceuticals Reports Record Annual Revenues for the Full Year 2016 of $4.8 Million Company Affirms Revenue Guidance of $15 Million for Fiscal Year 2017

SEC Connect Exhibit 99.1 Innovus Pharmaceuticals Reports Record Annual Revenues for the Full Year 2016 of $4.8 Million Company Affirms Revenue Guidance of $15 Million for Fiscal Year 2017 SAN DIEGO, March 6, 2017 ? Innovus Pharmaceuticals, Inc., (?Innovus Pharma?) (OTCQB: INNV), today announced full year 2016 net revenues of $4.8 million compared to $0.7 million in revenues for the same period in

Innovus Pharmaceuticals FORM 8-K (Current Report/Significant Event)

SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation

H.C. Wainwright and Co., LLC Engagement Agreement, dated January 17, 2017, filed as an exhibit to the Registrant’s registration statement on Form S-1, filed with the SEC on February 1, 2017, and incorporated herein by reference.

As filed with the Securities and Exchange Commission on February 1, 2017 Registration No.

Innovus Pharma Expands its Executive Management Team with the Addition of Randy Berholtz as its Executive Vice President, Corporate Development and General Counsel Pharma Corporate and Legal veteran Berholtz comes on board as Innovus expands its corp

SEC Connect Exhibit 99.1 Innovus Pharma Expands its Executive Management Team with the Addition of Randy Berholtz as its Executive Vice President, Corporate Development and General Counsel Pharma Corporate and Legal veteran Berholtz comes on board as Innovus expands its corporate development and commercialization efforts San Diego, Calif., January 6, 2017 ? Innovus Pharmaceuticals, Inc. ("Innovus

EX-99.2

SEC Connect

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2017 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissi

Employment Agreement, between Innovus Pharmaceuticals, Inc. and Randy Berholtz, dated January 9, 2017, filed as an exhibit to the Registrant’s current report on Form 8-K, filed with the SEC on January 6, 2017, and incorporated herein by reference.

SEC Connect Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into by and between Randy Berholtz (?you? or ?your?) and Innovus Pharmaceuticals, Inc., a Nevada corporation (the ?Company?). This Agreement has an effective date of January 9, 2017 (the ?Effective Date?). In consideration of the mutual covenants and promises made in this Agreement, you and the Com

INNV / Innovus Pharmaceuticals, Inc. / Novalere Holdings, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Innovus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45778V106 (CUSIP Number) Novalere Holdings, LLC 151 Tremont Street, Penthouse Boston, MA 02111 With a copy to: Gil Arie, Esq. Foley Hoag LLP 155

FIRST AMENDMENT TO AMENDMENT AND SUPPLEMENT

EX-99.6 2 v454363ex6.htm EXHIBIT 6 Exhibit 6 FIRST AMENDMENT TO AMENDMENT AND SUPPLEMENT This FIRST AMENDMENT TO AMENDMENT AND SUPPLEMENT (this “First Amendment”) is entered into as of November 30, 2016 by and among Innovus Pharmaceuticals, Inc., Nevada corporation (“Acquiror”), and Novalere Holdings, LLC, a Delaware limited liability company (“Stockholder”). Acquiror and Stockholder each, a “Part

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 innv8knov262016.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 26, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or Other J

Innovus Pharma Signs $2 Million a Year Exclusive License and Distribution Agreement with J&H Co. LTD for Zestra® for Female Sexual Arousal in South Korea Agreement Currently Expected to Add $20 million in Revenues Over the Life of the Agreement

Untitled Document Exhibit 99.1 Innovus Pharma Signs $2 Million a Year Exclusive License and Distribution Agreement with J&H Co. LTD for Zestra? for Female Sexual Arousal in South Korea Agreement Currently Expected to Add $20 million in Revenues Over the Life of the Agreement San Diego, CA, November 29, 2016 ? Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the ?Company?) (OTCQB Venture Market:

Amended and Restated Articles of Incorporation of the Registrant as filed with the Office of the Secretary of State of the State of Nevada on October 10, 2016, filed as an exhibit to the Registrant’s registration statement on Form S-8, filed with the SEC on November 28, 2016, and incorporated herein by reference.

SEC Connect Exhibit 4.01 CERTIFICATE OF AMENDED AND RESTATED ARTICLES OF INCORPORATION OF INNOVUS PHARMACEUTICALS, INC. Pursuant to the provisions of Nevada Revised Statutes 78.390 and 78.403, the undersigned officer of Innovus Pharmaceuticals, Inc., a Nevada corporation, does hereby certify as follows: A. The board of directors of the corporation has duly adopted resolutions proposing to amend an

INNOVUS PHARMACEUTICALS, INC. AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN EFFECTIVE AS OF OCTOBER 10, 2016

SEC Connect Exhibit 4.03 INNOVUS PHARMACEUTICALS, INC. AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN EFFECTIVE AS OF OCTOBER 10, 2016 SECTION 1. INTRODUCTION. The Company?s Board of Directors adopted this Innovus Pharmaceuticals, Inc. Amended and Restated 2016 Equity Incentive Plan (the ?Plan?) effective on the Effective Date. The purpose of the Plan is to promote the long-term success of the Co

Amended and Restated Bylaws of the Registrant, filed as an exhibit to the Registrant’s registration statement on Form S-8, filed with the SEC on November 28, 2016, and incorporated herein by reference.

SEC Connect Exhibit 4.2 AMENDED AND RESTATED BYLAWS of INNOVUS PHARMACEUTICALS, INC. a Nevada corporation ARTICLE I OFFICES Section 1.1 Principal Office. The principal office and place of business of Innovus Pharmaceuticals, Inc., a Nevada corporation (the ?Corporation?) shall be established from time to time by resolution of the board of directors of the Corporation (the ?Board of Directors?). Se

Amended and Restated 2016 Equity Incentive Plan of the Registrant, filed as an exhibit to the Registrant’s registration statement on Form S-8, filed with the SEC on November 28, 2016, and incorporated herein by reference.

SEC Connect As filed with the Securities and Exchange Commission on November 28, 2016 Registration No.

Submission of Matters to a Vote of Security Holders

SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 18, 2016 (November 16, 2016) INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisd

EX-99.1

EX 991 Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 17, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA (State or Other Jurisdiction of Incorporation) 000-52991 90-08

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended September 30, 2016 [ ] Transition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended September 30, 2016 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991 INNOVUS PHARMACEU

AMENDMENT AND SUPPLEMENT

EXHIBIT 10.2 AMENDMENT AND SUPPLEMENT THIS AMENDMENT AND SUPPLEMENT (this ?Amendment and Supplement?) is entered into as of November 12, 2016 (the ?Effective Date?), to the Registration Rights and Stock Restriction Agreement, dated as of February 4, 2015 ( the ?Agreement?) by and among Innovus Pharmaceuticals, Inc., a Nevada corporation (?Acquiror?), and Novalere Holdings, LLC, a Delaware limited

Innovus Pharma Reports Record Quarterly Revenues for the Third Quarter of 2016 Increasing 947% to $1.9 Million and Record Nine Months Ended September 2016 Revenues Increasing 463% to $3.1 Million Company Affirms Revenue Guidance of $5 Million for Fis

SEC Connect Exhibit 99.1 Innovus Pharma Reports Record Quarterly Revenues for the Third Quarter of 2016 Increasing 947% to $1.9 Million and Record Nine Months Ended September 2016 Revenues Increasing 463% to $3.1 Million Company Affirms Revenue Guidance of $5 Million for Fiscal Year 2016 SAN DIEGO, November 10, 2016 ? Innovus Pharmaceuticals, Inc., (?Innovus Pharma?) (OTCQB: INNV), today announced

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 innv8knov102016.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 10, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or Other J

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 1, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA (State or Other Jurisdiction of Incorporation) 000-52991 90-0814124 (Commis

EX-99.1

SEC Connect Exhibit 99.1

Innovus Pharmaceuticals DEFINITIVE SCHEDULE 14A

SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

EX-99.1

EX-99.1 2 ex991.htm CORPORATE PRESENTATION FOR OCTOBER 2016

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) October 17, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA (State or Other Jurisdiction of Incorporation) 000-52991 90-0814124 (Commis

Innovus Pharmaceuticals PRELIMINARY SCHEDULE 14A

PRE 14A 1 innvpre14a.htm PRELIMINARY SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi

Innovus Pharmaceuticals ESP

CORRESP 1 filename1.htm October 6, 2016 VIA EDGAR Sharon M. Blume Accounting Branch Chief United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Innovus Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2015 Filed March 30, 2016 File No. 000-52991 Dear Ms. Blume: On behalf of Innovus Pharmaceuticals, Inc. (“

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 9, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA (State or Other Jurisdiction of Incorporation) 000-52991 90-0814124 (Commi

EX-99.1

ex99-1.htm

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 29, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or other jurisdiction of incorporation) (Commissi

Employment Agreement, between Innovus Pharmaceuticals, Inc. and Robert Hoffman, dated September 6, 2016, filed as an exhibit to the Registrant’s current report on Form 8-K, filed with the SEC on August 29, 2016 and incorporated herein by reference.

ex10-1.htm Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into by and between Robert Hoffman (?you? or ?your?) and Innovus Pharmaceuticals, Inc., a Nevada corporation (the ?Company?). This Agreement has an effective date of September 6, 2016 (the ?Effective Date?). In consideration of the mutual covenants and promises made in this Agreement, you and the Co

With Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman as its Chief Financial Officer Pharma veteran Hoffman comes on board as Innovus exceeds expectations for revenues and cash flow, and will work to up-list the company to a higher national e

ex99-1.htm Exhibit 99.1 With Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman as its Chief Financial Officer Pharma veteran Hoffman comes on board as Innovus exceeds expectations for revenues and cash flow, and will work to up-list the company to a higher national exchange San Diego, Calif., August 29, 2016 – Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an

Innovus Pharmaceuticals, Inc. 25,591,881 Shares of Common Stock Offered by the Selling Stockholders

Filed Pursuant to Rule 424(b)(2) Registration No. 333-213016 PROSPECTUS Innovus Pharmaceuticals, Inc. 25,591,881 Shares of Common Stock Offered by the Selling Stockholders Offering Price Per Share Total Common Stock – 13,871,881 Shares underlying Convertible Promissory Notes… $ 0.25 $ 3,467,970 Common Stock – 3,000,000 Shares underlying Warrants… $ 0.40 $ 1,200,000 Common Stock – 7,500,000 Issuanc

Innovus Pharmaceuticals, Inc. 25,591,881 Shares of Common Stock Offered by the Selling Stockholders

Filed Pursuant to Rule 424(b)(2) Registration No. 333-213016 PROSPECTUS Innovus Pharmaceuticals, Inc. 25,591,881 Shares of Common Stock Offered by the Selling Stockholders Offering Price Per Share Total Common Stock – 13,871,881 Shares underlying Convertible Promissory Notes… $ 0.25 $ 3,467,970 Common Stock – 3,000,000 Shares underlying Warrants… $ 0.40 $ 1,200,000 Common Stock – 7,500,000 Issuanc

Innovus Pharmaceuticals ESP

August 24, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporate Finance Securities and Exchange Commission 100 F.

Innovus Pharmaceuticals ESP

August 24, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporate Finance Securities and Exchange Commission 100 F.

Innovus Pharmaceuticals FORM S-1/A

S-1/A 1 innvs1a2-aug2016.htm FORM S-1/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 2) Commission File Number 333-213016 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 2834 (Primary St

Innovus Pharmaceuticals FORM S-1/A

S-1/A 1 innvs1a2-aug2016.htm FORM S-1/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 2) Commission File Number 333-213016 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 2834 (Primary St

Innovus Pharmaceuticals ESP

CORRESP 1 filename1.htm Weintraub LAW GROUP PC Business and Corporate Finance 10085 CARROLL CANYON ROAD, SUITE 230 SAN DIEGO, CALIFORNIA 92131 TELEPHONE (858) 566-7010 FACSIMILE (858) 566-7015 [email protected] August 24, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporate Finance Securities and Exchange Commission 100 F. Street N.E. Washington,

Innovus Pharmaceuticals ESP

CORRESP 1 filename1.htm Weintraub LAW GROUP PC Business and Corporate Finance 10085 CARROLL CANYON ROAD, SUITE 230 SAN DIEGO, CALIFORNIA 92131 TELEPHONE (858) 566-7010 FACSIMILE (858) 566-7015 [email protected] August 24, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporate Finance Securities and Exchange Commission 100 F. Street N.E. Washington,

Innovus Pharmaceuticals FORM S-1

S-1/A 1 innvs1a1-aug2016.htm FORM S-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 1) Commission File Number 333-213016 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 2834 (Primary Stan

Innovus Pharmaceuticals FORM S-1

S-1/A 1 innvs1a1-aug2016.htm FORM S-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 1) Commission File Number 333-213016 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 2834 (Primary Stan

Innovus Pharmaceuticals ESP

CORRESP 1 filename1.htm Weintraub LAW GROUP PC Business and Corporate Finance 10085 CARROLL CANYON ROAD, SUITE 230 SAN DIEGO, CALIFORNIA 92131 TELEPHONE (858) 566-7010 FACSIMILE (858) 566-7015 [email protected] August 23, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporate Finance Securities and Exchange Commission 100 F. Street N.E. Washington,

Innovus Pharmaceuticals ESP

CORRESP 1 filename1.htm Weintraub LAW GROUP PC Business and Corporate Finance 10085 CARROLL CANYON ROAD, SUITE 230 SAN DIEGO, CALIFORNIA 92131 TELEPHONE (858) 566-7010 FACSIMILE (858) 566-7015 [email protected] August 23, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporate Finance Securities and Exchange Commission 100 F. Street N.E. Washington,

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) August 18, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA (State or Other Jurisdiction of Incorporation) 000-52991 90-0814124 (Commiss

EX-99

ex99-1.htm

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) August 18, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA (State or Other Jurisdiction of Incorporation) 000-52991 90-0814124 (Commiss

EX-99

ex99-1.htm

10% Debenture, filed as an exhibit to the Registrant's Current Report on Form 8-K, filed with the SEC on August 15, 2016, and incorporated herein by reference.

Exhibit 4.5 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended June 30, 2016 [ ] Transition Repor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended June 30, 2016 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991 INNOVUS PHARMACEUTICAL

Securities Purchase Agreement, filed as an exhibit to the Registrant's Current Report on Form 8-K, filed with the SEC on August 15, 2016, and incorporated herein by reference.

Exhibit 4.6 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of May 6, 2016, is entered into by and between Innovus Pharmaceuticals, Inc., a Nevada corporation, (the ?Company?), and Vista Capital Investments, LLC (the ?Buyer?). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registr

Promissory Note, filed as an exhibit to the Registrant's Current Report on Form 8-K, filed with the SEC on August 15, 2016, and incorporated herein by reference.

Exhibit 4.7 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS PROMISSORY HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUAN

Promissory Note, filed as an exhibit to the Registrant's Current Report on Form 8-K, filed with the SEC on August 15, 2016, and incorporated herein by reference.

Exhibit 4.7 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS PROMISSORY HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended June 30, 2016 [ ] Transition Repor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended June 30, 2016 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991 INNOVUS PHARMACEUTICAL

10% Debenture, filed as an exhibit to the Registrant's Current Report on Form 8-K, filed with the SEC on August 15, 2016, and incorporated herein by reference.

Exhibit 4.5 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, T

Innovus Pharma Turns Cash Flow Positive with Over $1 Million in Revenues for the Second Quarter 2016 Company Affirms its Previously Announced Revenue Guidance of $5 Million for 2016

ex99-1.htm Exhibit 99.1 Innovus Pharma Turns Cash Flow Positive with Over $1 Million in Revenues for the Second Quarter 2016 Company Affirms its Previously Announced Revenue Guidance of $5 Million for 2016 San Diego, Calif., August 9, 2016 ? Innovus Pharmaceuticals, Inc., (?Innovus Pharma?) www.innovuspharma.com (OTCQB: INNV) announced today that the Company turned cash flow positive with over $25

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 9, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Commission File Number 333-206890 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its cha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Commission File Number 333-206890 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 98-0814124 (

Garden State Securities Engagement Agreement, filed as an exhibit to the Registrant's Registration Statement on Form S-1, filed with the SEC on August 9, 2016, and incorporated herein by reference.

Exhibit 10.5 Garden State Securities Inc. 328 Newman Springs Rd. Red Bank, NJ 07707 March 25, 2015 INNOVUS PHARMACEUTICALS, INC. 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 ATT: Dr. Bassam Damaj, Chief Executive Officer Re: Engagement Agreement Dear Dr. Damaj, This letter sets forth the Agreement (the “Letter Agreement”) by and among Innovus Pharmaceuticals, Inc. and its subsidiaries a

SECURITIES PURCHASE AGREEMENT

EX-10.1 3 ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June , 2016, by and between INNOVUS PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 (the “Company”), and [ ], a [ ] company, with its address [ ] (the

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of June, 2016, by and between INNOVUS PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 (the “Company”), and [ ], a [ ] company, with its address at [ ] (the “Buyer”). This Agreement is being ent

INNOVUS PHARMACEUTICALS, INC. Common Stock Purchase Warrant

Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

H.C. Wainwright and Co., LLC Engagement Agreement filed as an exhibit to the Registrant's Registration Statement on Form S-1, filed with the SEC on August 9, 2016, and incorporated herein by reference.

Exhibit 10.6 June 24, 2016 STRICTLY CONFIDENTIAL Innovus Pharmaceuticals, Inc. 9171 Towne Centre Drive, Suite 440 San Diego, California 92122 Attention: Dr. Bassam Damaj, Chief Executive Officer Dear Dr. Damaj: This letter agreement (this “Agreement”) constitutes the agreement between Innovus Pharmaceuticals, Inc. (the “Company”) and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (“Rodman”

CONVERTIBLE PROMISSORY NOTE

Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

First Amendment to the Securities Purchase Agreement filed as an exhibit to the Registrant's Registration Statement on Form S-1, filed with the SEC on August 9, 2016, and incorporated herein by reference.

Exhibit 10.7 FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT AND TRANSACTION DOCUMENTS This FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT (the ?Amendment?), dated as of July [ ], 2016, by and between INNOVUS PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 (the ?Company?), and [ ], a [ ] company, with its address

Innovus Pharmaceuticals Announces the Closing of its $3M Private Financing from Institutional Investors Company in a Strong Cash Position for Product Launches and Expedited Growth

ex99-1.htm Exhibit 99.1 Innovus Pharmaceuticals Announces the Closing of its $3M Private Financing from Institutional Investors Company in a Strong Cash Position for Product Launches and Expedited Growth SAN DIEGO, CA: August 1, 2016 – Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counte

Innovus Pharmaceuticals FORM 8-K (Current Report/Significant Event)

innv8kjuly252016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 25, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or Other Jurisdiction of Inc

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 22, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA (State or Other Jurisdiction of Incorporation) 000-52991 90-0814124 (Commissio

EX-99.1

ex99-1.htm

Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 15, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or Other Jurisdiction of Incorporation) (Commis

Innovus Pharmaceuticals Closes an Additional $0.75M for a Total of $2.25M in Financing from Institutional Investors Money Raised to Fast Track the Launch of FlutiCare™ in Anticipation of the FDA’s Upcoming Decision

ex99-1.htm Exhibit 99.1 Innovus Pharmaceuticals Closes an Additional $0.75M for a Total of $2.25M in Financing from Institutional Investors Money Raised to Fast Track the Launch of FlutiCare™ in Anticipation of the FDA’s Upcoming Decision SAN DIEGO, CA: July 18, 2016 – Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the co

INNOVUS PHARMACEUTICALS, INC. Common Stock Purchase Warrant

ex4-3.htm Exhibit 4.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATE

CONVERTIBLE PROMISSORY NOTE

EX-4.2 3 ex4-2.htm FORM OF CONVERTIBLE PROMISSORY NOTE Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE A

Innovus Pharmaceuticals Well Capitalized with the Closing of $1.5M in Financing from Institutional Investors Money Raised to Fast Track the Move to Being Cash Flow Positive in 2016

ex99-1.htm Exhibit 99.1 Innovus Pharmaceuticals Well Capitalized with the Closing of $1.5M in Financing from Institutional Investors Money Raised to Fast Track the Move to Being Cash Flow Positive in 2016 SAN DIEGO, CA: July 06, 2016 ? Innovus Pharmaceuticals, Inc. (?Innovus Pharma? or the ?Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counte

SECURITIES PURCHASE AGREEMENT

ex4-1.htm Exhibit 4.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of June 30, 2016, by and between INNOVUS PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 (the ?Company?), and [ ], a [ ] company, with its address [ ] (the ?Buyer?). WHEREAS: A. The Company and the Buyer

REGISTRATION RIGHTS AGREEMENT

ex4-4.htm Exhibit 4.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of June, 2016, by and between INNOVUS PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 (the ?Company?), and [ ], a [ ] company, with its address at [ ] (the ?Buyer?). This Agreement is

Unregistered Sales of Equity Securities, Financial Statements and Exhibits

innv8kjul52016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 30, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or Other Jurisdiction of Incor

Innovus Pharmaceuticals Well Capitalized with the Closing of $1.5M in Financing from Institutional Investors Money Raised to Fast Track the Move to Being Cash Flow Positive in 2016

ex99-1.htm Exhibit 99.1 Innovus Pharmaceuticals Well Capitalized with the Closing of $1.5M in Financing from Institutional Investors Money Raised to Fast Track the Move to Being Cash Flow Positive in 2016 SAN DIEGO, CA: July 06, 2016 ? Innovus Pharmaceuticals, Inc. (?Innovus Pharma? or the ?Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counte

Form of Common Stock Purchase Warrant Agreement, dated June 30, 2016, filed as an exhibit to the Registrant's current report on Form 8-K, filed with the SEC on July 6, 2016, and incorporated herein by reference.

ex4-3.htm Exhibit 4.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATE

Form of Convertible Promissory Note, dated June 30, 2016, filed as an exhibit to the Registrant's current report on Form 8-K, filed with the SEC on July 6, 2016, and incorporated herein by reference.

ex4-2.htm Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATE

Form of Securities Purchase Agreement, dated June 30, 2016, filed as an exhibit to the Registrant's current report on Form 8-K, filed with the SEC on July 6, 2016, and incorporated herein by reference.

ex4-1.htm Exhibit 4.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of June 30, 2016, by and between INNOVUS PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 (the ?Company?), and [ ], a [ ] company, with its address [ ] (the ?Buyer?). WHEREAS: A. The Company and the Buyer

Form of Registration Rights Agreement, filed as an exhibit to the Registrant's current report on Form 8-K, filed with the SEC on July 6, 2016, and incorporated herein by reference.

EX-4.4 5 ex4-4.htm FORM OF REGISTRATION RIGHTS AGREEMENT Exhibit 4.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of June, 2016, by and between INNOVUS PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 (the “Company”), and [ ], a [ ] company, with its a

Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 30, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or Other Jurisdiction of Incorporation) (Commissi

Innovus Pharma Signs Exclusive License and Distribution Agreement with BroadMed for EjectDelay® in Lebanon -Innovus Eligible to Receive up to $6.2 Million in Upfront and Sales Milestone Payments plus Transfer Price

Exhibit 99.1 Innovus Pharma Signs Exclusive License and Distribution Agreement with BroadMed for EjectDelay® in Lebanon -Innovus Eligible to Receive up to $6.2 Million in Upfront and Sales Milestone Payments plus Transfer Price San Diego, Calif., May 25 2016 – Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that del

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 innv8kmay252016.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 25, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or Other Jurisd

Innovus Pharmaceuticals FORM 8-K (Current Report/Significant Event)

innv8kmay202016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 20, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA (State or Other Jurisdiction of Incorporation) 000-52991 90

Innovus Pharma CEO Provides Shareholder Update and Conference Call

EX-99.1 2 ex99-1.htm SHAREHOLDER UPDATE AND NOTICE OF CONFERENCE CALL, DATED MAY 20, 2016 Exhibit 99.1 Innovus Pharma CEO Provides Shareholder Update and Conference Call Management Files First Quarter 2016 Financials SAN DIEGO, CA, May 20, 2016 – Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, in

INNOVUS PHARMACEUTICALS, INC. 10% DEBENTURE $24,000 San Diego, CA Dated as of: May 3, 2016

Exhibit 4.5 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended March 31, 2016 [ ] Transition Repo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period ended March 31, 2016 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Exchange Act. For the transition period from to . Commission File Number: 000-52991 INNOVUS PHARMACEUTICA

Innovus Pharmaceuticals, Inc. Promissory Note

EX-4.7 4 ex4-7.htm PROMISSORY NOTE Exhibit 4.7 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS PROMISSORY HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NO

SECURITIES PURCHASE AGREEMENT

Exhibit 4.6 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May 6, 2016, is entered into by and between Innovus Pharmaceuticals, Inc., a Nevada corporation, (the “Company”), and Vista Capital Investments, LLC (the “Buyer”). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2015 Commission file number: 000-52991 INNOV

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2015 Commission file number: 000-52991 INNOVUS PHARMACEUTICALS, INC. (Name of registrant as specified in its charter) Nevada 90-0814124 (State or other jurisdiction of incorporation or organizat

Subsidiaries of the Registrant

EX-21.1 3 ex211.htm SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 Subsidiaries of the Registrant Subsidiary Jurisdiction of Incorporation FasTrack Pharmaceuticals, Inc. Delaware Semprae Laboratories, Inc. Delaware Novalere, Inc. Delaware

CODE OF ETHICS

Exhibit 14.1 CODE OF ETHICS Innovus Pharmaceuticals, Inc. (the "Company") is committed to conducting its business in compliance with all the applicable laws and regulations of the countries in which it operates and in accordance with high standards of business conduct. The Company strives to maintain the highest standard of accuracy, completeness and disclosure in its financial dealings, records a

INNV / Innovus Pharmaceuticals, Inc. / Damaj Bassam - SCHEDULE 13D Activist Investment

SC 13D 1 innv13dmar2016.htm SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. ) INNOVUS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45778V106

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 innv8kmar222016.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 22, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or Other Juri

Innovus Pharma CEO Interviewed on CEOLIVE.Tv Dr. Damaj Notes the Beyond Human $2.2M Product Acquisition, the Projected Move to Profitability and the Plans for Future Uplisting to the NYSE

ex99-1.htm Exhibit 99.1 Innovus Pharma CEO Interviewed on CEOLIVE.Tv Dr. Damaj Notes the Beyond Human $2.2M Product Acquisition, the Projected Move to Profitability and the Plans for Future Uplisting to the NYSE SAN DIEGO, CA, March 22, 2016 ? Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innov

EX-99.1

innvex99-1.htm Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 14, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA (State or Other Jurisdiction of Incorporation) 000-52991 90-0814124 (Commissi

Security Agreement, dated February 19, 2016 by and among the Company and SBI Investments, LLC 2014-1, filed as an exhibit to the Registrant’s report on Form 8-K with the SEC on March 1, 2016, and incorporated herein by reference.

ex2-3.htm Exhibit 2.3 SECURITY AGREEMENT SECURITY AGREEMENT, dated as of February 19, 2016 (this ?Agreement?), between Innovus Pharmaceuticals, Inc., a Nevada corporation (the ?Grantor?), and SBI Investments LLC, 2014-1, or its registered assigns (the ?Secured Party?). The Grantor and the Secured Party are or will be parties to a certain Purchase Agreement (as amended, amended and restated, supple

Innovus Pharmaceuticals Announces the Closing of the Acquisition of All of Beyond Human, LLC’s Products which Generated over $2.2 Million in Sales in 2015

ex99-1.htm Exhibit 99.1 Innovus Pharmaceuticals Announces the Closing of the Acquisition of All of Beyond Human, LLC?s Products which Generated over $2.2 Million in Sales in 2015 SAN DIEGO, CA: March 1st, 2016 ? Innovus Pharmaceuticals, Inc., (?Innovus Pharma? or the ?Company) www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter (?OTC?) and consumer p

20% Secured Promissory Note, dated February 19, 2016 by and among the Company ad SBI Investments, LLC 2014-1, filed as an exhibit to the Registrant’s report on Form 8-K with the SEC on March 1, 2016, and incorporated herein by reference.

ex2-2.htm Exhibit 2.2 20% SECURED PROMISSORY NOTE February 19, 2016 Original Principal Amount: $550,000 FOR VALUE RECEIVED, Innovus Pharmaceuticals, Inc., a Nevada corporation (the ?Maker?), with its principal offices located at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122, promises to pay to the order of SBI Investments LLC, 2014-1, or its registered assigns (the ?Payee?), upon the ter

Form of Purchase Agreement, dated February 19, 2016, by and among the Company and SBI Investments, LLC 2014-1, filed as an exhibit to the Registrant’s report on Form 8-K with the SEC on March 1, 2016, and incorporated herein by reference.

EX-2.1 2 ex2-1.htm PURCHASE AGREEMENT, DATED FEBRUARY 19, 2016, BY AND AMONG THE COMPANY AND SBI INVESTMENTS, LLC 2014-1 Exhibit 2.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of February 19, 2016, is entered into by and between Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and SBI Investments LLC, 2014-1 (as the “Lender”). Capitalized terms used

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 24, 2016 INNOVUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-52991 90-0814124 (State or Other Jurisdiction of Incorporation) (Comm